ST Germain D J Co. Inc. Has $869,000 Stock Position in Danaher Co. (NYSE:DHR)

ST Germain D J Co. Inc. grew its position in Danaher Co. (NYSE:DHR) by 1.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,125 shares of the conglomerate’s stock after acquiring an additional 48 shares during the period. ST Germain D J Co. Inc.’s holdings in Danaher were worth $869,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Swedbank AB acquired a new position in Danaher during the 1st quarter worth about $676,545,000. TD Asset Management Inc grew its position in shares of Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the period. Finally, Castle Hook Partners LP acquired a new position in shares of Danaher in the first quarter worth approximately $98,913,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Leerink Partners increased their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Evercore ISI boosted their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen raised their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, Barclays increased their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $274.38 on Friday. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The firm has a market cap of $203.23 billion, a price-to-earnings ratio of 46.51, a PEG ratio of 4.49 and a beta of 0.83. The company has a fifty day moving average price of $270.72 and a 200-day moving average price of $260.02. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. As a group, equities research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.